Lattice Biologics Ltd (CVE:LBL) shares traded down 14.3% during trading on Wednesday . The company traded as low as C$0.03 and last traded at C$0.03. 406,287 shares were traded during mid-day trading, a decline of 33% from the average session volume of 609,796 shares. The stock had previously closed at C$0.04.
The company has a market cap of $3.74 million and a P/E ratio of -2.31.
Lattice Biologics Company Profile (CVE:LBL)
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The company offers AmnioBoost, an allograft amniotic fluid visco supplement for the treatment of joint pain associated with osteoarthritis, as well as traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts.
Read More: Price-Sales Ratio
Receive News & Ratings for Lattice Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lattice Biologics and related companies with MarketBeat.com's FREE daily email newsletter.